New melanoma research published by Dr Tim (Wei) Wang from the Crown Princess Mary Cancer Centre, Westmead Hospital, has shown the concurrent use of two drugs that slow the growth of metastatic melanoma, Dabrafenib and Trametinib, are safe to use during palliative radiation therapy. 

The study found these BRAF inhibitor drugs, which were previously reported to increase toxicity, had no grade 3 or 4 radiotherapy related toxicities. The phase I/II trial ‘CombiRT’ trial studied 10 patients, and was developed and led by MASC Trials.

Read the paper in the Journal of Clinical and Translational Radiation Oncology.